Core Insights - Gossamer Bio, Inc. is under investigation by Levi & Korsinsky for potential violations of federal securities laws [1] Group 1: Company Overview - Gossamer Bio's lead pipeline candidate, Seralutinib, was evaluated in the PROSERA study, a pivotal Phase 3 trial for pulmonary arterial hypertension [2] - The PROSERA patient population was characterized by the company as well-suited to demonstrate a treatment effect [2] Group 2: Trial Results - During the Q1 2025 earnings call, CEO Faheem Hasnain expressed optimism about the trial results, stating that baseline characteristics were "precisely what we have targeted" and that the company had "over 90% power given the sample size" [3] - Despite reaching the planned enrollment target, the primary efficacy endpoint of the trial did not achieve the prespecified level of statistical significance [3]

Core Viewpoint - Gossamer Bio, Inc. is under investigation by Levi & Korsinsky for potential violations of federal securities laws, particularly related to its lead pipeline candidate, Seralutinib, and the PROSERA study results [1][4]. Group 1: Company Overview - Gossamer Bio's lead pipeline candidate is Seralutinib, which was evaluated in the PROSERA study, a pivotal Phase 3 trial for pulmonary arterial hypertension [2]. - The PROSERA patient population was characterized by the company as well-suited to demonstrate a treatment effect [2]. Group 2: Trial Results - During the Q1 2025 earnings call, CEO Faheem Hasnain expressed optimism about the trial results, stating that the baseline characteristics were "precisely what we have targeted" and that the company had "over 90% power given the sample size" [3]. - Despite reaching the planned enrollment target, the primary efficacy endpoint of the trial did not achieve the prespecified level of statistical significance [3].

Group 1 - Gossamer Bio, Inc. is under investigation by Levi & Korsinsky for potential violations of federal securities laws [1] - The company's lead pipeline candidate, Seralutinib, was evaluated in the PROSERA study, a pivotal Phase 3 trial for pulmonary arterial hypertension [2] - During the Q1 2025 earnings call, the CEO expressed optimism about the trial's results, stating that the baseline characteristics were targeted and that there was "over 90% power given the sample size," although the primary efficacy endpoint did not achieve statistical significance [3] Group 2 - Levi & Korsinsky has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders and being recognized as one of the top securities litigation firms in the U.S. for seven consecutive years [5]

Core Viewpoint - Gossamer Bio, Inc. is under investigation by Levi & Korsinsky for potential violations of federal securities laws, particularly related to the results of its pivotal Phase 3 trial for the drug Seralutinib [1]. Group 1: Company Overview - Gossamer Bio's lead pipeline candidate is Seralutinib, which was evaluated in the PROSERA study for pulmonary arterial hypertension [2]. - The PROSERA trial reached its planned enrollment target, but the primary efficacy endpoint did not achieve the prespecified level of statistical significance [3]. Group 2: Management Statements - During the Q1 2025 earnings call, CEO Faheem Hasnain expressed optimism about the trial results, stating that the baseline characteristics were "precisely what we have targeted" and that the company had "over 90% power given the sample size" [3].

Core Viewpoint - Gossamer Bio, Inc. is under investigation by Levi & Korsinsky for potential violations of federal securities laws, particularly related to the results of its pivotal Phase 3 trial for the drug Seralutinib [1]. Group 1: Company Overview - Gossamer Bio's lead pipeline candidate is Seralutinib, which was evaluated in the PROSERA study for pulmonary arterial hypertension [2]. - The PROSERA trial aimed to demonstrate a treatment effect in a patient population that the company believed was well-suited for the study [2]. Group 2: Trial Results - During the Q1 2025 earnings call, CEO Faheem Hasnain expressed optimism about the trial results, stating that the baseline characteristics were targeted and that the company had "over 90% power given the sample size" [3]. - Despite reaching the planned enrollment target, the primary efficacy endpoint of the trial did not achieve the prespecified level of statistical significance [3].

Phase 3 PROSERA Topline Results February 2026 Forward Looking Statements This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, prospective products, product approvals, research and development costs, timing and likelihood of success, plans and objectives of management for future operations, and future results of c ...

Core Viewpoint - Gossamer Bio Inc. (NASDAQ:GOSS) is highlighted as a promising multibagger stock, primarily due to its lead asset, Seralutinib, which targets pulmonary arterial hypertension (PAH) [1] Group 1: Stock Performance - The stock has seen significant growth, rising from approximately $1 at the beginning of the year to $2.50, resulting in nearly 180% returns year-to-date [1] - Analyst sentiment has strengthened, with a Buy rating from Piper Sandler and a price target of $15 reiterated [2] - H.C. Wainwright also reaffirmed a Buy rating with a target of $10, indicating confidence in Seralutinib [3] Group 2: Drug Development and Trials - Recent literature reviews and trial extensions have bolstered optimism around Seralutinib, with Phase 2 study data showing benefits sustained for 72 weeks, including reduced pulmonary vascular resistance and improved six-minute walk distance [4] - The potential for Seralutinib to be used in combination with other therapies could expand its application in pulmonary treatment [5] - The upcoming Phase 3 PROSERA trial, with results expected in February 2026, is identified as a significant upcoming catalyst for the company [5] Group 3: Company Overview - Gossamer Bio Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for pulmonary and cardiovascular diseases [5]